HC Wainwright restated their buy rating on shares of Karuna Therapeutics ( NASDAQ:KRTX – Free Report ) in a report released on Thursday morning, Benzinga reports. They currently have a $300.00 target price on the stock. Other analysts have also issued research reports about the company. 58.com reissued a maintains rating on shares of Karuna Therapeutics in a research note on Monday, June 5th. Morgan Stanley reissued an overweight rating and set a $280.00 price target on shares of Karuna Therapeutics in a research report on Friday, August 4th.
https://www.dailypolitical.com/2023/10/01/karuna-therapeutics-krtx-buy-rating-reaffirmed-at-hc-wainwright.html#dailypolitical
Du måste logga in före du kommenterar